Medikine

Executive Summary

Medikine is a San Diego-based biotechnology company founded in 2018 that specializes in discovering and engineering cytokine mimetics through its proprietary PEPTIKINES platform. By combining peptide library screening, combinatorial synthetic peptide ligation, and protein engineering, the company designs modular therapeutics that mimic natural cytokines while overcoming their inherent limitations, such as poor stability, short half-life, and pleiotropic side effects. This approach has the potential to unlock new therapeutic applications across immunology, oncology, and inflammatory diseases, where cytokine signaling plays a critical role. Medikine's platform is differentiated by its ability to generate highly selective and potent cytokine mimetics that can be fine-tuned for specific receptor interactions, offering a more controlled and safer alternative to native cytokines.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Financing Round60% success
• Q1 2027Lead Program IND Filing40% success
• Q2 2026Research Collaboration or Licensing Deal50% success